Cytalux (pafolacianince), a drug that binds to Ovarian cancer tissue and glows when exposed to fluorescent light, has been approved by the U.S. Food and Drug Administration (FDA) to help surgeons detect Ovarian tumors during surgical procedures in patients.
A Purdue University spokesperson told Fox News that Philip Low, Purdue University’s Presidential Scholar for Drug Discovery, invented the drug. Low described in a press release that when a surgeon turns on the near-infrared light during the surgery, those lesions light up like stars against a night sky.
Dr. Sunil Singhal, along with colleagues at the Center for Precision Surgery in the Abramson Cancer Center at the University of Pennsylvania in partnership with On Target Laboratories, led one of the largest clinical trial sites in the country for Cytalux. The university researchers said this new technology provides surgeons with a guide that goes beyond what is seen with the naked eye or touch, especially when the lesions are small.